Tasso, Inc., a Seattle, WA-based blood collection startup, completed a $6.1m financing round.
The round was led by Vertical Venture Partners, with participation from Techstars and Cedars-Sinai.
The company intends to use the funds to launch its first product and grow the team to support significant commercial interest.
Led by Ben Casavant, co-founder and CEO, Tasso is advancing the development of Tasso OnDemand, which enables pateints to self-collect blood samples and mail them back to the lab for analysis. It gives researchers insight during drug development and allows healthcare practitioners to manage care, selecting the best drug for each patient, minimizing side effects, and ensuring high adherence to treatment.
The product is anticipated to be available for purchase in Q2 2019.
This funding builds upon $13.1m of grant funding received from DARPA, DTRA, and NIH.